1
|
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov 2024:OF1-OF14. [PMID: 38583184 DOI: 10.1158/2159-8290.cd-24-0102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 03/08/2024] [Accepted: 03/22/2024] [Indexed: 04/09/2024]
Abstract
Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product, was developed for the treatment of advanced or refractory ccRCC. We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial. No patients encountered dose-limiting toxicity, and disease control was achieved in 81.3% of patients. One patient remains in a durable complete response at 3 years. Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. These data represent a proof of concept for the treatment of ccRCC and other CD70+ malignancies with CD70-targeted allogeneic CAR T cells. SIGNIFICANCE Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors.
Collapse
Affiliation(s)
- Sumanta K Pal
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California
| | - Ben Tran
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - John B A G Haanen
- Netherlands Cancer Institute, Amsterdam, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | | | - Adrian Sacher
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
- Departments of Medicine and Immunology, University of Toronto, Toronto, Canada
| | - Nizar M Tannir
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Lihua E Budde
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California
| | - Simon J Harrison
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | | | - Sagar S Patel
- Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Luis Meza
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California
| | | | - Anna Ma
- CRISPR Therapeutics, Boston, Massachusetts
| | | | | | | | - Ellen B Gurary
- Formerly employed by CRISPR Therapeutics, Boston, Massachusetts
| | - Henia Dar
- CRISPR Therapeutics, Boston, Massachusetts
| | | | - Changan Guo
- Formerly employed by CRISPR Therapeutics, Boston, Massachusetts
| | | | | | - Phuong K Morrow
- Formerly employed by CRISPR Therapeutics, Boston, Massachusetts
| | - Neeraj Agarwal
- Division of Medical Onco-logy, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Samer A Srour
- University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
2
|
He C, Maniyar RR, Avraham Y, Zappasodi R, Rusinova R, Newman W, Heath H, Wolchok JD, Dahan R, Merghoub T, Meyerson JR. Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Sci Adv 2022; 8:eabm4552. [PMID: 35213218 PMCID: PMC8880771 DOI: 10.1126/sciadv.abm4552] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Accepted: 01/12/2022] [Indexed: 05/11/2023]
Abstract
GITR is a TNF receptor, and its activation promotes immune responses and drives antitumor activity. The receptor is activated by the GITR ligand (GITRL), which is believed to cluster receptors into a high-order array. Immunotherapeutic agonist antibodies also activate the receptor, but their mechanisms are not well characterized. We solved the structure of full-length mouse GITR bound to Fabs from the antibody DTA-1. The receptor is a dimer, and each subunit binds one Fab in an orientation suggesting that the antibody clusters receptors. Binding experiments with purified proteins show that DTA-1 IgG and GITRL both drive extensive clustering of GITR. Functional data reveal that DTA-1 and the anti-human GITR antibody TRX518 activate GITR in their IgG forms but not as Fabs. Thus, the divalent character of the IgG agonists confers an ability to mimic GITRL and cluster and activate GITR. These findings will inform the clinical development of this class of antibodies for immuno-oncology.
Collapse
Affiliation(s)
- Changhao He
- Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA
| | - Rachana R. Maniyar
- Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Yahel Avraham
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Roberta Zappasodi
- Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medicine, New York, NY, USA
- Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
| | - Radda Rusinova
- Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA
| | | | | | - Jedd D. Wolchok
- Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medicine, New York, NY, USA
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Rony Dahan
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Taha Merghoub
- Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Weill Cornell Medicine, New York, NY, USA
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Joel R. Meyerson
- Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA
| |
Collapse
|
3
|
He C, Maniyar RR, Avraham Y, Zappasodi R, Rusinova R, Newman W, Heath H, Wolchok JD, Dahan R, Merghoub T, Meyerson J. Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Biophys J 2022. [DOI: 10.1016/j.bpj.2021.11.2277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Aliberti R, Ambrosino F, Ammendola R, Angelucci B, Antonelli A, Anzivino G, Arcidiacono R, Bache T, Baeva A, Baigarashev D, Barbanera M, Bernhard J, Biagioni A, Bician L, Biino C, Bizzeti A, Blazek T, Bloch-Devaux B, Bonaiuto V, Boretto M, Bragadireanu AM, Britton D, Brizioli F, Brunetti MB, Bryman D, Bucci F, Capussela T, Carmignani J, Ceccucci A, Cenci P, Cerny V, Cerri C, Checcucci B, Conovaloff A, Cooper P, Cortina Gil E, Corvino M, Costantini F, Cotta Ramusino A, Coward D, D'Agostini G, Dainton JB, Dalpiaz P, Danielsson H, De Simone N, Di Filippo D, Di Lella L, Doble N, Duk V, Duval F, Döbrich B, Emelyanov D, Engelfried J, Enik T, Estrada-Tristan N, Falaleev V, Fantechi R, Fascianelli V, Federici L, Fedotov S, Filippi A, Fiorini M, Fry JR, Fu J, Fucci A, Fulton L, Gamberini E, Gatignon L, Georgiev G, Ghinescu SA, Gianoli A, Giorgi M, Giudici S, Gonnella F, Goudzovski E, Graham C, Guida R, Gushchin E, Hahn F, Heath H, Henshaw J, Holzer EB, Husek T, Hutanu OE, Hutchcroft D, Iacobuzio L, Iacopini E, Imbergamo E, Jenninger B, Jerhot J, Jones RWL, Kampf K, Kekelidze V, Kholodenko S, Khoriauli G, Khotyantsev A, Kleimenova A, Korotkova A, Koval M, Kozhuharov V, Kucerova Z, Kudenko Y, Kunze J, Kurochka V, Kurshetsov V, Lamanna G, Lanfranchi G, Lari E, Latino G, Laycock P, Lazzeroni C, Lehmann Miotto G, Lenti M, Leonardi E, Lichard P, Litov L, Lollini R, Lomidze D, Lonardo A, Lubrano P, Lupi M, Lurkin N, Madigozhin D, Mannelli I, Mapelli A, Marchetto F, Marchevski R, Martellotti S, Massarotti P, Massri K, Maurice E, Medvedeva M, Mefodev A, Menichetti E, Migliore E, Minucci E, Mirra M, Misheva M, Molokanova N, Moulson M, Movchan S, Napolitano M, Neri I, Newson F, Norton A, Noy M, Numao T, Obraztsov V, Ostankov A, Padolski S, Page R, Palladino V, Parenti A, Parkinson C, Pedreschi E, Pepe M, Perrin-Terrin M, Peruzzo L, Petrov P, Petrov Y, Petrucci F, Piandani R, Piccini M, Pinzino J, Polenkevich I, Pontisso L, Potrebenikov Y, Protopopescu D, Raggi M, Romano A, Rubin P, Ruggiero G, Ryjov V, Salamon A, Santoni C, Saracino G, Sargeni F, Schuchmann S, Semenov V, Sergi A, Shaikhiev A, Shkarovskiy S, Soldi D, Sozzi M, Spadaro T, Spinella F, Sturgess A, Sugonyaev V, Swallow J, Trilov S, Valente P, Velghe B, Venditti S, Vicini P, Volpe R, Vormstein M, Wahl H, Wanke R, Wrona B, Yushchenko O, Zamkovsky M, Zinchenko A. Search for Lepton Number and Flavor Violation in K^{+} and π^{0} Decays. Phys Rev Lett 2021; 127:131802. [PMID: 34623867 DOI: 10.1103/physrevlett.127.131802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 07/22/2021] [Indexed: 06/13/2023]
Abstract
Searches for the lepton number violating K^{+}→π^{-}μ^{+}e^{+} decay and the lepton flavor violating K^{+}→π^{+}μ^{-}e^{+} and π^{0}→μ^{-}e^{+} decays are reported using data collected by the NA62 experiment at CERN in 2017-2018. No evidence for these decays is found and upper limits of the branching ratios are obtained at 90% confidence level: B(K^{+}→π^{-}μ^{+}e^{+})<4.2×10^{-11}, B(K^{+}→π^{+}μ^{-}e^{+})<6.6×10^{-11} and B(π^{0}→μ^{-}e^{+})<3.2×10^{-10}. These results improve by 1 order of magnitude over previous results for these decay modes.
Collapse
Affiliation(s)
- R Aliberti
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - F Ambrosino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - R Ammendola
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - B Angelucci
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Antonelli
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Anzivino
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - R Arcidiacono
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - T Bache
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Baeva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Baigarashev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Barbanera
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Bernhard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Biagioni
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - L Bician
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Biino
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A Bizzeti
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Blazek
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - B Bloch-Devaux
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - V Bonaiuto
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - M Boretto
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A M Bragadireanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Britton
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - F Brizioli
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M B Brunetti
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Bryman
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - F Bucci
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Capussela
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - J Carmignani
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - A Ceccucci
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Cenci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - V Cerny
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Cerri
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - B Checcucci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - A Conovaloff
- George Mason University, Fairfax, Virginia 22030, USA
| | - P Cooper
- George Mason University, Fairfax, Virginia 22030, USA
| | - E Cortina Gil
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Corvino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Costantini
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | | | - D Coward
- George Mason University, Fairfax, Virginia 22030, USA
| | - G D'Agostini
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - J B Dainton
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - P Dalpiaz
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - H Danielsson
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - N De Simone
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Di Filippo
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - L Di Lella
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - N Doble
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Duk
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - F Duval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - B Döbrich
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Emelyanov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - J Engelfried
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - T Enik
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Estrada-Tristan
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - V Falaleev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Fantechi
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Fascianelli
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - L Federici
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Fedotov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Filippi
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Fiorini
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - J R Fry
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - J Fu
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - A Fucci
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - L Fulton
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gamberini
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Gatignon
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - G Georgiev
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S A Ghinescu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - A Gianoli
- INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Giorgi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - S Giudici
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - F Gonnella
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Goudzovski
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - C Graham
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - R Guida
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Gushchin
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - F Hahn
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - H Heath
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - J Henshaw
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E B Holzer
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Husek
- Charles University, 116 36 Prague 1, Czech Republic
| | - O E Hutanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - L Iacobuzio
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Iacopini
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Imbergamo
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - B Jenninger
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - J Jerhot
- Charles University, 116 36 Prague 1, Czech Republic
| | - R W L Jones
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - K Kampf
- Charles University, 116 36 Prague 1, Czech Republic
| | - V Kekelidze
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - S Kholodenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Khoriauli
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Khotyantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Kleimenova
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - A Korotkova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Koval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Kozhuharov
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - Z Kucerova
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - J Kunze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - V Kurochka
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - V Kurshetsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Lamanna
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Lanfranchi
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - E Lari
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Latino
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - P Laycock
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - C Lazzeroni
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - G Lehmann Miotto
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - M Lenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Leonardi
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lichard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Litov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Lollini
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - D Lomidze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Lonardo
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lubrano
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Lupi
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - N Lurkin
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Madigozhin
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - I Mannelli
- Scuola Normale Superiore e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Mapelli
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - F Marchetto
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - R Marchevski
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Martellotti
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Massarotti
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - K Massri
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Maurice
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - M Medvedeva
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Mefodev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - E Menichetti
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Migliore
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Minucci
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Mirra
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - M Misheva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Molokanova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Moulson
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Movchan
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Napolitano
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - I Neri
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - F Newson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Norton
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Noy
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Numao
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - V Obraztsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Ostankov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - S Padolski
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - R Page
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - V Palladino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Parenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - C Parkinson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Pedreschi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - M Pepe
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Perrin-Terrin
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Peruzzo
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - P Petrov
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - Y Petrov
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - F Petrucci
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Piandani
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Piccini
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Pinzino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - I Polenkevich
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - L Pontisso
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - Yu Potrebenikov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | | | - M Raggi
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - A Romano
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - P Rubin
- George Mason University, Fairfax, Virginia 22030, USA
| | - G Ruggiero
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - V Ryjov
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Salamon
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - C Santoni
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - G Saracino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Sargeni
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - S Schuchmann
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Semenov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Sergi
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Shaikhiev
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - S Shkarovskiy
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Soldi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Sozzi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - T Spadaro
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - F Spinella
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Sturgess
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - V Sugonyaev
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - J Swallow
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - S Trilov
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - P Valente
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - B Velghe
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S Venditti
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Vicini
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - R Volpe
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Vormstein
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - H Wahl
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Wanke
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - B Wrona
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - O Yushchenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - M Zamkovsky
- Charles University, 116 36 Prague 1, Czech Republic
| | - A Zinchenko
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| |
Collapse
|
5
|
Haas MS, Kagey MH, Heath H, Schuerpf F, Rottman JB, Newman W. mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment. Mol Cancer Res 2020; 19:717-725. [PMID: 33443105 DOI: 10.1158/1541-7786.mcr-20-0799] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 11/13/2020] [Accepted: 12/17/2020] [Indexed: 11/16/2022]
Abstract
Dickkopf-1 (DKK1), a secreted modulator of Wnt signaling, is overexpressed in many cancers, is often associated with worse clinical outcomes, and has been shown to have immunosuppressive effects. DKN-01 is an IgG4 clinical stage antibody that potently and specifically neutralizes human and murine DKK1 and has recently completed a promising study in combination with pembrolizumab in patients with gastric/gastroesophageal junction cancer. The purpose of this study is to characterize a murine version of DKN-01 (mDKN-01) and to better understand its mechanism of action. We examined the efficacy of mDKN-01 in both melanoma and metastatic breast cancer models. Immune depletion experiments revealed a requirement for natural killer (NK) but not B and T cells for tumor growth inhibition. mDKN-01 treatment promotes the induction of the NK-activating cytokines IL15 and IL33 as well as an enhanced recruitment of CD45+ cells. Other treatment-related changes include a reduction of Gr-1+CD11b+ myeloid-derived suppressor cells (MDSC) in the tumor and spleen and the upregulation of PD-L1 on MDSCs. In addition, mDKN-01 has a marked effect at reducing pulmonary metastases in the mouse 4T1 breast cancer model. Finally, the mDKN-01/anti-PD-1 combination was more effective at inhibiting melanoma growth than mDKN-01 alone. Taken together, our data demonstrate that mDKN-01 has efficacy by blocking the immunosuppressive effects of DKK1 in the tumor microenvironment (TME) and provides insight into the clinical activity observed with DKN-01-based treatment. IMPLICATIONS: mDKN-01 reverses a DKK1-mediated innate immune suppression in the TME and has additive efficacy with a PD-1 inhibitor.
Collapse
|
6
|
Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, Newman W, Sirard CA, Fleisher M, Morris MJ, Chen Y, Larson SM, Haffner MC, Nelson PS, Schultz N, Garabedian MJ, Scher HI, Logan SK, Sawyers CL. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2020; 4:2000097. [PMID: 33015525 DOI: 10.1200/po.20.00097] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/12/2020] [Indexed: 12/31/2022] Open
Abstract
PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) with low androgen receptor (AR) and without neuroendocrine signaling, termed double-negative prostate cancer (DNPC), is increasingly prevalent in patients treated with AR signaling inhibitors and is in need of new biomarkers and therapeutic targets. METHODS Candidate genes enriched in DNPC were determined using differential gene expression analysis of discovery and validation cohorts of mCRPC biopsies. Laboratory studies were carried out in human mCRPC organoid cultures, prostate cancer (PCa) cell lines, and mouse xenograft models. Epigenetic studies were carried out in a rapid autopsy cohort. RESULTS Dickkopf-1 (DKK1) expression is increased in DNPC relative to prostate-specific antigen (PSA)-expressing mCRPC in the Stand Up to Cancer/Prostate Cancer Foundation discovery cohort (11.2 v 0.28 reads per kilobase per million mapped reads; q < 0.05; n = 117) and in the University of Washington/Fred Hutchinson Cancer Research Center cohort (9.2 v 0.99 fragments per kilobase of transcript per million mapped reads; P < .0001). DKK1 expression can be regulated by activated Wnt signaling in vitro and correlates with activating canonical Wnt signaling mutations and low PSA mRNA in mCRPC biopsies (P < .05). DKK1 hypomethylation was associated with increased DKK1 mRNA expression (Pearson r = -0.66; P < .0001) in a rapid autopsy cohort (n = 7). DKK1-high mCRPC biopsies are infiltrated with significantly higher numbers of quiescent natural killer (NK) cells (P < .005) and lower numbers of activated NK cells (P < .0005). Growth inhibition of the human PCa model PC3 by the anti-DKK1 monoclonal antibody DKN-01 depends on the presence of NK cells in a severe combined immunodeficient xenograft mouse model. CONCLUSION These results support DKK1 as a contributor to the immunosuppressive tumor microenvironment of DNPC. These data have provided the rationale for a clinical trial targeting DKK1 in mCRPC (ClinicalTrials.gov identifier: NCT03837353).
Collapse
Affiliation(s)
- David R Wise
- Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY
| | | | - Joshua Armenia
- Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Victor Adorno Febles
- Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY
| | - Bridget McLaughlin
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Ryan Brennan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Katie L Thoren
- Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Wassim Abida
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Karen S Sfanos
- Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD.,Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD.,Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD
| | - Angelo M De Marzo
- Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD.,Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD.,Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD
| | - Srinivasan Yegnasubramanian
- Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD.,Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD
| | - Josef J Fox
- Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | | | | - Martin Fleisher
- Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Michael J Morris
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Yu Chen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Steven M Larson
- Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Michael C Haffner
- Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD.,Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD
| | - Peter S Nelson
- Departments of Medicine and Pathology, University of Washington, and Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Nikolaus Schultz
- Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Michael J Garabedian
- Department of Urology, NYU Langone Medical Center, New York, NY.,Department of Microbiology, NYU Langone Medical Center, New York, NY
| | - Howard I Scher
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Susan K Logan
- Department of Urology, NYU Langone Medical Center, New York, NY
| | - Charles L Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.,Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY
| | | |
Collapse
|
7
|
Zappasodi R, Heath H, Zhang Y, Haas M, Yang M, Mirabelli C, Wolchok JD, Sirard C, Newman W, Merghoub T. Abstract 2402: GITR cancer immunotherapy: Epitope swapping of anti-GITR TRX518 to inform functional translatability from mouse to human. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: At 52.5% identity in their extracellular domains (ECDs), mouse and human GITR (CD357) sequences are only modestly conserved. Thus transitioning promising murine anti-tumor activity data with the anti-GITR DTA-1 and 2F8 Mabs to clinical trials with the non-crossreactive anti-human GITR Mab TRX518 poses a considerable limitation. Here we investigated three elements of the GITR mouse and human antibodies to address this limitation: 1) the functional epitopes targeted by anti-human GITR (TRX-518) and anti-murine GITR (DTA-1 and 2F8) antibodies; 2) their biological activities on primary T cells; and 3) the role of anti-GITR Fc receptor engagement.
Results and Conclusions: Alanine scanning, amino acid substitutions and flow cytometry experiments were performed to define critical residues important for the binding of all three Mabs to their respective GITR targets. Swaps of 5-8 of these critical residues showed both the loss of murine and the gain of human directed Mab binding when residues critical for TRX18 binding were substituted into murine GITR. Likewise, the substitution of residues critical for DTA-1/2F8 binding into human GITR resulted in loss of TRX518 binding and the gain of 2F8/DTA-1 binding. We then mapped these critical residues to 3D structural models of the murine and human GITR ECDs built by contact-map guided fragment assembly simulations. Regions defined by these critical residues showed a high degree of overlap, indicating structural conservation even without amino acid identity. Thus the epitopes defined by both DTA-1 and 2F8 are homologous to those defined on human GITR by TRX518. In in vitro standard proliferation/suppression assays with effector T cells (Teff) and regulatory T cells (Tregs) isolated from human healthy donors and naïve mice respectively, TRX518, similarly to DTA-1, significantly increased proliferation, activation and pro-inflammatory cytokine production of human and murine Teff cultured alone or in the presence of Tregs. These observations indicate that Mabs directed to similar mouse and human GITR ECD epitopes result in similar biological activities. Lastly, we questioned the importance of a functional Fc domain in anti-GITR Mabs in order to translate these in vitro effects into anti-tumor activity in vivo. To this end, we compared the anti-tumor activity of DTA-1 and its aglycosyl version in the aggressive and poorly immunogenic B16 melanoma model. Both Fc and non-Fc binding DTA-1 were able to control tumor growth. This suggests that the aglycosyl-anti-GITR Mab TRX518 has the potential to be effective in the clinic despite the lack of Fc receptor engagement. These results align with our preliminary results in patients treated with TRX518 monotherapy showing reductions in Treg frequencies both in tumor biopsies and in the periphery. TRX518 would therefore appear to be well-poised for use in the treatment of solid tumor malignancies.
Note: This abstract was not presented at the meeting.
Citation Format: Roberta Zappasodi, Heidi Heath, Yang Zhang, Michael Haas, Min Yang, Christopher Mirabelli, Jedd D. Wolchok, Cyndi Sirard, Walter Newman, Taha Merghoub. GITR cancer immunotherapy: Epitope swapping of anti-GITR TRX518 to inform functional translatability from mouse to human [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2402.
Collapse
Affiliation(s)
| | | | | | | | - Min Yang
- 2Leap Therapeutics, Cambridge, MA
| | | | | | | | | | - Taha Merghoub
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
8
|
Haas M, Heath H, Wu Y, Zhang X, Sirard C, He X, Newman W, Kagey M. Abstract 1710: DKN-01, a therapeutic DKK1 neutralizing antibody, has immune modulatory activity in nonclinical tumor models. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-1710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Wnt signaling is a fundamental pathway that is dysregulated in oncology. The Wnt signaling modulator DKK1 is expressed in a variety of tumor types and elevated levels frequently correlate with poor survival. DKK1 promotes tumor growth by stimulating proliferation, metastasis, and angiogenesis, and has been implicated in contributing to an immune suppressive tumor microenvironment. DKN-01 is a humanized monoclonal therapeutic antibody that binds DKK1 with high affinity and selectivity. It is currently being evaluated clinically as a monotherapy and in combination in a variety of solid tumors. Here we describe further characterization of the mechanism of action of DKN-01 and demonstrate immune mediated anti-tumor activity in nonclinical models. A murine version of DKN-01 (mDKN-01) has efficacy in a syngeneic melanoma B16 tumor model. However, mDKN-01 is unable to impede B16 tumor growth in NSG immunodeficient mice, indicating that a functioning immune system is required for antibody activity. Furthermore, preliminary data suggest that mDKN-01 is targeting a myeloid derived suppressor cell population in the tumor microenvironment. These data support an immune mediated mechanism of action of DKN-01 and provide a rationale for clinical development in combination with immunotherapy agents. The first clinical study evaluating DKN-01 in combination with pembrolizumab has initiated enrollment in patients with relapse/refractory esophagogastric malignancies.
Citation Format: Michael Haas, Heidi Heath, Yinyuan Wu, Xinjun Zhang, Cynthia Sirard, Xi He, Walter Newman, Michael Kagey. DKN-01, a therapeutic DKK1 neutralizing antibody, has immune modulatory activity in nonclinical tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1710.
Collapse
Affiliation(s)
| | | | | | | | | | - Xi He
- 2Harvard Medical School, Boston, MA
| | | | | |
Collapse
|
9
|
Lamanna G, Aliberti R, Ambrosino F, Ammendola R, Angelucci B, Antonelli A, Anzivino G, Arcidiacono R, Barbanera M, Biagioni A, Bician L, Biino C, Bizzeti A, Blazek T, Bloch-Devaux B, Bonaiuto V, Boretto M, Bragadireanu M, Britton D, Brizioli F, Brunetti M, Bryman D, Bucci F, Capussela T, Ceccucci A, Cenci P, Cerny V, Cerri C, Checcucci B, Conovaloff A, Cooper P, Cortina Gil E, Corvino M, Costantini F, Cotta Ramusino A, Coward D, D’Agostini G, Dainton J, Dalpiaz P, Danielsson H, De Simone N, Di Filippo D, Di Lella L, Doble N, Dobrich B, Duval F, Duk V, Engelfried J, Enik T, Estrada-Tristan N, Falaleev V, Fantechi R, Fascianelli V, Federici L, Fedotov S, Filippi A, Fiorini M, Fry J, Fu J, Fucci A, Fulton L, Gamberini E, Gatignon L, Georgiev G, Ghinescu S, Gianoli A, Giorgi M, Giudici S, Gonnella F, Goudzovski E, Graham C, Guida R, Gushchin E, Hahn F, Heath H, Husek T, Hutanu O, Hutchcroft D, Iacobuzio L, Iacopini E, Imbergamo E, Jenninger B, Kampf K, Kekelidze V, Kholodenko S, Khoriauli G, Khotyantsev A, Kleimenova A, Korotkova A, Koval M, Kozhuharov V, Kucerova Z, Kudenko Y, Kunze J, Kurochka V, Kurshetsov V, Lanfranchi G, Lamanna G, Latino G, Laycock P, Lazzeroni C, Lenti M, Lehmann Miotto G, Leonardi E, Lichard P, Litov L, Lollini R, Lomidze D, Lonardo A, Lubrano P, Lupi M, Lurkin N, Madigozhin D, Mannelli I, Mannocchi G, Mapelli A, Marchetto F, Marchevski R, Martellotti S, Massarotti P, Massri K, Maurice E, Medvedeva M, Mefodev A, Menichetti E, Migliore E, Minucci E, Mirra M, Misheva M, Molokanova N, Moulson M, Movchan S, Napolitano M, Neri I, Newson F, Norton A, Noy M, Numao T, Obraztsov V, Ostankov A, Padolski S, Page R, Palladino V, Parkinson C, Pedreschi E, Pepe M, Perrin-Terrin M, Peruzzo L, Petrov P, Petrucci F, Piandani R, Piccini M, Pinzino J, Polenkevich I, Pontisso L, Potrebenikov Y, Protopopescu D, Raggi M, Romano A, Rubin P, Ruggiero G, Ryjov V, Salamon A, Santoni C, Saracino G, Sargeni F, Semenov V, Sergi A, Shaikhiev A, Shkarovskiy S, Soldi D, Sougonyaev V, Sozzi M, Spadaro T, Spinella F, Sturgess A, Swallow J, Trilov S, Valente P, Velghe B, Venditti S, Vicini P, Volpe R, Vormstein M, Wahl H, Wanke R, Wrona B, Yushchenko O, Zamkovsky M, Zinchenko A. NA62 and NA48/2 results on search for Heavy Neutral Leptons. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201817901009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
In this paper we present new results on upper limits for the search of Heavy Neutral Leptons (HNL) with data collected by NA48/2 (2003-2004), NA62-RK (2007) and NA62 (2015) CERN experiments. The data collected with different trigger configuration allow to search for both long and short living heavy neutrinos in the mass range below the kaon mass. In addition the status of the search for K+ → π+vv with the NA62 detector will be briefly presented.
Collapse
|
10
|
Abstract
Safeguarding vulnerable older people is the responsibility of all healthcare professionals, but what this means in reality and how it can be achieved in practice is not always well understood. This article provides guidance on how government initiatives can be used by nurses to improve the care of older people. The article identifies criteria for determining when a concern should be raised as a safeguarding alert and when neglect may be occurring. A positive culture encompassing zero tolerance of poor care in the hospital setting is advocated.
Collapse
|
11
|
Heath H. Anonymity rights. Br Dent J 2010; 209:105. [DOI: 10.1038/sj.bdj.2010.679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
12
|
Affiliation(s)
- H Heath
- Department of Chemical Pathology, University College Hospital Medical School, London
| | | | | |
Collapse
|
13
|
Lyons S, Richardson M, Bishop P, Smith J, Heath H, Giesen J. Excess post-exercise oxygen consumption in untrained men following exercise of equal energy expenditure: comparisons of upper and lower body exercise. Diabetes Obes Metab 2007; 9:889-94. [PMID: 17924871 DOI: 10.1111/j.1463-1326.2006.00679.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIM This study assessed excess post-exercise oxygen consumption (EPOC) following continuous 200- kcal bouts of upper body exercise (UBE) and lower body exercise (LBE). METHODS Ten untrained men (age: 25.7 +/- 5.83 years; arm VO(2peak): 2.2 +/- 0.25 l/min; 21.5 +/- 4.35 ml/kg/min; leg VO(2peak): 3.1 +/- 0.38 l/min; 30.7 +/- 7.79 ml/kg/min) exercised at 60% mode-specific VO(2) peak using either an arm crank or a leg cycle protocol (counterbalanced order with 48 h between). Baseline VO(2) was monitored for 30 min. EPOC was measured until baseline was re-established. RESULTS EPOC magnitude and duration were significantly greater (p < 0.05) following LBE (2.93 +/- 1.4 l/min; 16.5 +/- 7.4 min) compared with UBE (1.89 +/- 0.7 l/min; 11.5 +/- 6.1 min). CONCLUSIONS Results indicate that leg exercise elicited a greater EPOC magnitude and duration compared with arm exercise of the same relative intensity and energy expenditure.
Collapse
Affiliation(s)
- S Lyons
- Department of Physical Education and Recreation, Western Kentucky University, Bowling Green, KY, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Höög A, Heath H, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002; 32:676-80. [PMID: 12434154 DOI: 10.1038/ng1048] [Citation(s) in RCA: 458] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2002] [Accepted: 10/24/2002] [Indexed: 11/09/2022]
Abstract
We report here the identification of a gene associated with the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. A single locus associated with HPT-JT (HRPT2) was previously mapped to chromosomal region 1q25-q32. We refined this region to a critical interval of 12 cM by genotyping in 26 affected kindreds. Using a positional candidate approach, we identified thirteen different heterozygous, germline, inactivating mutations in a single gene in fourteen families with HPT-JT. The proposed role of HRPT2 as a tumor suppressor was supported by mutation screening in 48 parathyroid adenomas with cystic features, which identified three somatic inactivating mutations, all located in exon 1. None of these mutations were detected in normal controls, and all were predicted to cause deficient or impaired protein function. HRPT2 is a ubiquitously expressed, evolutionarily conserved gene encoding a predicted protein of 531 amino acids, for which we propose the name parafibromin. Our findings suggest that HRPT2 is a tumor-suppressor gene, the inactivation of which is directly involved in predisposition to HPT-JT and in development of some sporadic parathyroid tumors.
Collapse
Affiliation(s)
- J D Carpten
- Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Heath H. Good ideas--poor experiences. Nurs Older People 2001; 13:3. [PMID: 12008562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
17
|
Heath H. Nursing or personal care--who decides? Nurs Older People 2001; 13:3. [PMID: 12008551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
18
|
|
19
|
Heath H, White I. Sexuality and older people: an introduction to nursing assessment. Nurs Older People 2001; 13:29-31. [PMID: 12008627 DOI: 10.7748/nop.13.4.29.s15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- H Heath
- Centre for Cancer and Palliative Care Studies, Institute of Cancer Research, London
| | | |
Collapse
|
20
|
Masterson A, Heath H, Ford P, Cann P. A special case. Nurs Older People 2001; 13:7. [PMID: 12008632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
21
|
Heath H. The dilemmas of putting a price on care. Nurs Older People 2001; 13:3. [PMID: 12008407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
22
|
Abstract
Estrogen, one of several sex steroid hormones, mediates its actions through the estrogen receptor. The estrogen receptor (ER) has two subtypes, ER alpha and ER beta, each of which predominates in specific tissues and organs. Cofactor proteins interact with the ER to maximize ligand-dependent transactivation of target-gene promoters. The estrogen response element is the final step in estrogen-mediated gene regulation, and current research is focused on alternate response elements. The resulting biologic action can vary according to the specific type of ER, cofactor milieu, response element, and ligand. Selective estrogen receptor modulators (SERMs) exhibit tissue-specific estrogen agonist or antagonist activity. The SERM raloxifene, which binds to ER and targets a distinct DNA element, may distinguish agonist vs antagonist activity by ER subtype and has unique activity among other SERMs because of its molecular conformation. Phytoestrogens, a potential alternative to hormone replacement therapy and for cancer prevention, do not consistently mimic estrogen's activity. Different types of phytoestrogens have different potencies, and taking high-dose supplements after menopause may not emulate the apparent benefits of lifelong consumption of phytoestrogen-rich diets. In conclusion, the complexity of estrogen action--through different ER subtypes, with various cofactors, on alternate response element--is further enhanced by ligands with selective estrogen activity. Additional research is needed to elucidate these pathways and the resulting biological effects.
Collapse
Affiliation(s)
- V Krishnan
- Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
| | | | | |
Collapse
|
23
|
Heath H. Nursing homes--crisis of escalating closures. Nurs Older People 2001; 12:3. [PMID: 12008365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
24
|
Andrew DP, Ruffing N, Kim CH, Miao W, Heath H, Li Y, Murphy K, Campbell JJ, Butcher EC, Wu L. C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. J Immunol 2001; 166:103-11. [PMID: 11123282 DOI: 10.4049/jimmunol.166.1.103] [Citation(s) in RCA: 161] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CCR4, a chemokine receptor for macrophage-derived chemokine (MDC) and thymus and activation-regulated chemokine (TARC), has been implicated as a preferential marker for Th2 lymphocytes. Following in vitro polarization protocols, most Th2 lymphocytes express CCR4 and respond to its ligands TARC and MDC, whereas Th1 lymphocytes express CXC chemokine receptor 3 and CCR5 (but not CCR4). We show in this study that CCR4 is a major receptor for MDC and TARC on T lymphocytes, as anti-CCR4 mAbs significantly inhibit the migration of these cells to MDC and TARC. CCR4 is also highly expressed in most single-positive CD4(+) thymocytes and on a major fraction of blood nonintestinal (alpha(4)beta(7)(-)) memory CD4 lymphocytes, including almost all skin memory CD4(+) cells expressing the cutaneous lymphocyte Ag (CLA), but weakly or not expressed in other subsets in thymus and blood. Interestingly, major fractions of circulating CCR4(+) memory CD4 lymphocytes coexpress the Th1-associated receptors CXC chemokine receptor 3 and CCR5, suggesting a potential problem in using these markers for Th1 vs Th2 lymphocyte cells. Moreover, although production of Th2 cytokines in blood T cells is associated with CCR4(+) CD4 lymphocytes, significant numbers of freshly isolated circulating CCR4(+) memory CD4 lymphocytes (including both CLA(+) and CLA(-) fractions) readily express the Th1 cytokine IFN-gamma after short-term stimulation. Our results are consistent with a role for CCR4 as a major trafficking receptor for systemic memory T cells, and indicate that the patterns and regulation of chemokine receptor expression in vivo are more complex than indicated by current in vitro models of Th1 vs Th2 cell generation.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/metabolism
- Antibodies, Monoclonal/pharmacology
- Antigens, Differentiation, T-Lymphocyte
- Antigens, Neoplasm
- Binding Sites, Antibody
- Binding, Competitive/immunology
- CD4 Antigens/biosynthesis
- CD4-Positive T-Lymphocytes/metabolism
- CD8-Positive T-Lymphocytes/metabolism
- Cell Differentiation/immunology
- Cell Lineage/immunology
- Cell Migration Inhibition
- Cell Polarity/immunology
- Chemokine CCL17
- Chemokine CCL22
- Chemokines, CC/antagonists & inhibitors
- Chemokines, CC/blood
- Chemokines, CC/metabolism
- Child
- Cytokines/biosynthesis
- Humans
- Immunologic Memory
- Infant, Newborn
- Intestinal Mucosa/immunology
- Intestinal Mucosa/metabolism
- Lymphocyte Activation
- Membrane Glycoproteins/biosynthesis
- Mice
- Mice, Inbred C57BL
- Receptors, CCR4
- Receptors, CCR5/biosynthesis
- Receptors, CXCR3
- Receptors, Chemokine/biosynthesis
- Receptors, Chemokine/blood
- Receptors, Chemokine/genetics
- Receptors, Chemokine/immunology
- T-Lymphocyte Subsets/cytology
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/metabolism
- Th1 Cells/cytology
- Th1 Cells/immunology
- Th1 Cells/metabolism
- Th2 Cells/cytology
- Th2 Cells/immunology
- Th2 Cells/metabolism
- Transfection
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- D P Andrew
- Millennium Pharmaceuticals, Cambridge, MA 02139, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Johnston CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H, Gennari C, Christiansen C, Arnaud CD, Delmas PD. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160:3444-50. [PMID: 11112238 DOI: 10.1001/archinte.160.22.3444] [Citation(s) in RCA: 154] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND In postmenopausal women, raloxifene hydrochloride has favorable effects on bone and lipid metabolism and does not stimulate reproductive tissues. The studies reported herein evaluated the long-term (3-year) effects of raloxifene treatment on bone mineral density (BMD), serum lipid levels, and drug tolerability in healthy postmenopausal women. METHODS A total of 1145 healthy European and North American postmenopausal women aged 45 through 60 years were enrolled in 2 parallel, double-blind, randomized, placebo-controlled trials of identical design and randomly assigned to receive raloxifene hydrochloride, 30, 60, or 150 mg, or placebo daily; all groups received 400 to 600 mg of elemental calcium. Assessments included measurements for BMD by dual-energy x-ray absorptiometry, markers of bone turnover, and serum lipid levels. RESULTS Lumbar spine BMD changed from baseline to 36 months as follows: placebo (mean percentage change + SE), -1. 32% +0.22%; raloxifene, 30 mg, 0.71% +0.23%; raloxifene, 60 mg, 1. 28% +0.23%; and raloxifene, 150 mg, 1.20% +0.24%. Comparable BMD changes were observed in the hip and total body. Biochemical markers of bone turnover were suppressed by raloxifene to normal premenopausal ranges through 3 years. Serum low-density lipoprotein cholesterol was reduced 7% to 12% below baseline through 3 years. Study withdrawals due to any reason (37%) and withdrawals due to adverse events (14%) were not different among groups. The only significant adverse effect of therapy was hot flashes (25% in the 60-mg raloxifene group vs 18% in the placebo group); hot flashes were typically reported as mild and were not associated with study withdrawal (1.7% for 60-mg raloxifene vs 2.4% for placebo). CONCLUSIONS Raloxifene preserves BMD at important skeletal sites, lowers serum low-density lipoprotein cholesterol levels, and has a tolerability profile comparable to placebo. These results indicate a favorable benefit-risk profile of raloxifene for long-term use in healthy postmenopausal women. Arch Intern Med. 2000;160:3444-3450.
Collapse
Affiliation(s)
- C C Johnston
- Indiana University School of Medicine, Emerson Hall Room 421, 545 Barnhill Dr, Indianapolis, IN 46202, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Heath H. Tackling ageism--a new year resolution. Nurs Older People 2000; 12:3. [PMID: 12008376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/18/2023]
|
27
|
Heath H. The forgotten generation. Nurs Older People 2000; 12:10-3. [PMID: 12008383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
28
|
Abstract
As clinical supervision becomes more widely implemented in the United Kingdom with concerns and resistances being eroded as practitioners discover its benefits, it is important that potential limitations and perhaps failures are avoided. This paper utilizes Johns' (1996) intent-emphasis axis to explore how a technical interest, misunderstanding of expert practice, and confusion of self awareness with counselling, can detract from the supervisory process. Several of the criticisms of reflective practice will be examined to demonstrate where concerns are valid and where they may be based on misunderstandings and the need to control clinical supervision. Greater awareness of inappropriate emphasis and intent should enable even relatively inexperienced supervisors to help their supervisees move towards independence, emancipation and evolving expertise.
Collapse
Affiliation(s)
- H Heath
- School of Health Studies, Homerton College, Cambridge, England.
| | | |
Collapse
|
29
|
Abstract
The influence of care environments on patients has long been a fundamental concern for nurses. Considerations of how environments might be defined, particularly how multiple aspects of environments might impact on any individual, are complex. This article aims to unpick some of the complexities and to offer ideas on how nurses can positively influence environments, particularly in settings where older people live and are offered care.
Collapse
|
30
|
Heath H. Human rights--not best interests. Nurs Older People 2000; 12:3. [PMID: 12008397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
31
|
|
32
|
|
33
|
Heath H. Hidden talents: bringing out the dark horse. Nurs Older People 2000; 12:10-2. [PMID: 12008415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
34
|
Heath H, Cox DA, Plouffe L. Raloxifene therapy. J Am Geriatr Soc 2000; 48:1170-2. [PMID: 10983924 DOI: 10.1111/j.1532-5415.2000.tb04801.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Heath H. New plan--new look journal. Nurs Older People 2000; 12:3. [PMID: 12008420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
36
|
Glasby J, Heath H. Long-term issues. Nurs Older People 2000; 12:6-7. [PMID: 12008422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
37
|
Heath H. Assessing older people. Elder Care 2000; 11:27-8. [PMID: 11215974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
38
|
Heath H. Life across three centuries. Elder Care 1999; 11:6-8. [PMID: 11216287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
39
|
Heath H. Surmounting the barriers to care. Elder Care 1999; 11:29. [PMID: 10614297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
40
|
|
41
|
Heath H, Schofield I. Women's health. Growing old--staying healthy. Nurs Manag (Harrow) 1999; 5:28-32. [PMID: 10222983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
42
|
Hobbs MR, Pole AR, Pidwirny GN, Rosen IB, Zarbo RJ, Coon H, Heath H, Leppert M, Jackson CE. Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet 1999; 64:518-25. [PMID: 9973288 PMCID: PMC1377760 DOI: 10.1086/302259] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is an autosomal dominant disease characterized by the development of multiple parathyroid adenomas and multiple fibro-osseous tumors of the maxilla and mandible. Some families have had affected members with involvement of the kidneys, variously reported as Wilms tumors, nephroblastomas, and hamartomas. The HPT-JT gene (HRPT2) maps to chromosome 1q25-q31. We describe further investigation of two HPT-JT families (K3304 and K3349) identified through the literature. These two expanded families and two previously reported families were investigated jointly for linkage with 21 new, closely linked markers. Multipoint linkage analysis resulted in a maximum LOD score of 7.83 (at recombination fraction 0) for markers D1S2848-D1S191. Recombination events in these families reduced the HRPT2 region to approximately 14.7 cM. In addition, two of these four study families (i.e., K3304 and K11687) share a 2.2-cM length of their (expanded) affected haplotype, indicating a possible common origin. Combining the linkage data and shared-haplotype data, we propose a 0.7-cM candidate region for HRPT2.
Collapse
Affiliation(s)
- M R Hobbs
- Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Heath H, Rosenstein L, Hemmy L, Ferguson A, Karantzoulis N, Woolley K. Reliability and validity of the key search test. Arch Clin Neuropsychol 1999. [DOI: 10.1093/arclin/14.1.78] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Parsons A, Nachtigall L, Merritt D, Basson R, Heath H, Plouffe L. Vaginal Premarin® vs. Replens® in Women with Pre-existing Vaginal Atrophy Receiving Oral Placebo or Raloxifene: Effects on Objective Endpoints. Menopause 1999. [DOI: 10.1097/00042192-199906040-00073] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Abstract
Reflective practice aims to enhance client care via the professional development and growing expertise of practitioners. This paper offers practical guidelines for writing diaries that may form the basis for reflective practice, while acknowledging the skills that practitioners already use to examine their nursing actions and interactions. There is an emphasis on the outcomes of reflection as well as the reflections themselves, as this is seen as important if professional development is to be recognized and clients benefit. Time constraints that may make frequent formal reflection difficult are recognized by the format that allows deeper reflection where time permits and as skills develop. While ideas presented have been influenced by the literature on reflection, the paper owes as much to the continuing education students of the Homerton School of Health Studies who studied the reflective practice module during 1996. Without listening to their discussions, becoming aware of their difficulties and sharing their growing ability to reflect on practice, this article would not have been possible.
Collapse
Affiliation(s)
- H Heath
- Homerton School of Health Studies (Cambridge), Education Centre, Addenbrooke's Hospital, UK
| |
Collapse
|
46
|
Abstract
Debates within nursing can take the form of useful discussion and critique or verbal conflict generated from inflexible paradigm positions intolerant of differing stances perceived to be of no value. It is suggested that the most profitable process is debate that generates understanding of the strengths and limitations of various tools and techniques and helps identify suitable usage rather than uncritical advocacy or outright rejection. Suggested uses will thus themselves become subject to further debate and practitioners will be encouraged to adopt a use that suits their practice setting and role. The quantitative-qualitative research debate, criticisms of the nursing process and nursing models and reflective practice are examined. Dogmatic positions are highlighted and uses that are potentially controversial are identified.
Collapse
Affiliation(s)
- H Heath
- Homerton College, Cambridge School of Health Studies, England
| |
Collapse
|
47
|
Ford P, Heath H. The need for single registration care homes: the RCN vision. Elder Care 1998; 10:36-7. [PMID: 9855929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
48
|
Bryant HU, Kauffman RF, Iversen P, Cox DA, Mitlak BH, Heath H. Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83:3001-4. [PMID: 9709984 DOI: 10.1210/jc.83.8.3001-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
49
|
Heath H. Continuing the good work. Elder Care 1998; 10:38. [PMID: 9855930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
50
|
Abstract
The first article in this series, published last week, examined the current provision of care for older people in nursing and residential homes. The authors also detailed the RCN proposals in a report in last week's issue. This week, in the second of two articles, the authors discuss the divisions and polarisations which make the two-tier system unworkable for a client group with a wide range of needs.
Collapse
|